Protolan 30 mg is a proton pump inhibitor (PPI) formulated for the effective management of acid-related gastrointestinal disorders. It contains a substituted benzimidazole compound that works by profoundly reducing gastric acid secretion. Protolan 30 mg is widely used in the short-term and maintenance treatment of peptic ulcer disease, gastroesophageal reflux disease (GERD), and other conditions associated with excessive gastric acid production.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Therapeutic Class

Proton Pump Inhibitor

Pharmacology and Mode of Action

Protolan 30 mg acts by selectively inhibiting the H⁺/K⁺ ATPase enzyme system located in the gastric parietal cells. This enzyme represents the final step in gastric acid production. By blocking this pathway, Protolan effectively suppresses both basal and stimulated acid secretion, leading to reduced gastric acidity and promotion of mucosal healing. Due to its targeted mechanism, it provides sustained acid suppression with once-daily dosing in most patients.

Indications

Protolan 30 mg is indicated for the treatment and management of the following conditions:

• Short-term treatment of active duodenal ulcer

• Maintenance of healed duodenal ulcers

• Short-term treatment of active benign gastric ulcers

• Short-term treatment of active erosive esophagitis

• Maintenance of healing of erosive esophagitis

• Gastroesophageal reflux disease (GERD)

• Acid-related dyspepsia

• Pathological hypersecretory conditions, including Zollinger–Ellison syndrome

• Helicobacter pylori eradication (as part of combination therapy) to reduce the risk of duodenal ulcer recurrence

Dosage and Administration

Dosage should be individualized according to the condition being treated and patient response:

• Benign gastric ulcer: 30 mg once daily in the morning for 8 weeks

• Duodenal ulcer: 30 mg once daily for 4 weeks; maintenance dose 15 mg

• NSAID-associated ulcers: 15–30 mg daily for 4 weeks, extendable to 8 weeks if required

• GERD: 30 mg daily for 4 weeks; may be extended to 8 weeks; maintenance 15–30 mg daily

• Zollinger–Ellison syndrome: Initially 60 mg once daily, adjusted according to response; doses above 120 mg should be given in divided doses

• Acid-related dyspepsia: 15–30 mg daily for 2–4 weeks

Protolan 30 mg should preferably be taken in the morning before food.

Drug Interactions

Protolan 30 mg is a selective inhibitor of the cytochrome P-450 monooxygenase system. Although it may affect hepatic clearance of certain drugs, no clinically significant interactions have been widely reported. Reduced gastric acidity may influence vitamin B12 absorption and alter gastric bacterial colonization during long-term use.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Contraindications

Protolan 30 mg is contraindicated in patients with known hypersensitivity to any component of the formulation.

Side Effects

Common side effects include headache and dose-dependent diarrhea. Long-term use may lead to increased serum gastrin levels. In patients with Helicobacter pylori infection, prolonged therapy may accelerate the development of atrophic gastritis. Rare but serious effects related to prolonged acid suppression have been reported.

Pregnancy and Lactation

Protolan 30 mg should be avoided during pregnancy and lactation unless clearly indicated and prescribed by a physician.

Precautions and Warnings

Gastric malignancy should be excluded prior to therapy. Caution is advised in patients with hepatic impairment and during prolonged use.

Use in Special Populations

• Neonates: Not recommended due to lack of data

• Children: Clinical experience exists in patients aged 13 years and above

• Elderly: No dosage adjustment is generally required

Storage Conditions

Store at temperatures not exceeding 25°C. Protect from moisture and keep out of reach of children.